Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235135 | 0.79 | NOTUM (0.39) | HCAR1CNR2HTR2CHTR2BAADAT | |
| SCHEMBL2234758 | 0.75 | HCAR1 (0.36) | ALOX12HCAR1CNR2HTR2CHTR2B | |
| SCHEMBL2234256 | 0.72 | NOTUM (0.38) | HCAR1SRD5A1GAA | |
| SCHEMBL2232987 | 0.72 | ALDH1A1 (0.38) | HCAR1SRD5A1AADAT | |
| SCHEMBL2235165 | 0.72 | GABRG2 (0.50) | — | |
| SCHEMBL2233616 | 0.70 | L3MBTL1 (0.35) | ALOX12L3MBTL1 | |
| SCHEMBL2234607 | 0.69 | HCAR1 (0.40) | HCAR1SRD5A1GAAL3MBTL1 | |
| SCHEMBL2235371 | 0.66 | MAPT (0.37) | SRD5A1GAA | |
| SCHEMBL2235365 | 0.66 | MAPT (0.37) | SRD5A1GAA | |
| SCHEMBL11777465 | 0.66 | DRD4 (0.47) | ALOX12HCAR1CNR2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | ALOX12 2269/4885HCAR1 3057/4885CNR2 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.